Dyslipidemias

Metabolic·MeSH: Dyslipidemias

9 drugs in development·3 companies·16 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
monotherapy ezetimibe	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
monotherapy obicetrapib	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib + ezetimibe	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib + ezetimibe fdc	NEWAMSTERDAM PHARMA CO N.V. (NAMS)
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg q 2 weeks	NEWAMSTERDAM PHARMA CO N.V. (NAMS)

Phase 1(3)

Drug	Company
ARO-ANG3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-APOC3	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ly3885125	ELI LILLY & Co (LLY)

BioSniper tracks 9 drugs in development for Dyslipidemias across 3 companies.

There are 16 clinical trials targeting Dyslipidemias tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.